Share this page:
Due to the ongoing Ebola virus disease (Ebola) outbreak in the Democratic Republic of the Congo, subject matter experts from the Centers for Disease Control and Prevention (CDC) will discuss the current status of Ebola diagnostic testing that is available through the Laboratory Response Network (LRN) and CDC in the United States. The presenters will also discuss considerations around using OraQuick® Ebola Rapid Antigen Test (RDT), the first Ebola RDT that FDA has allowed for marketing in the United States.
During this COCA Call, clinicians will learn about options for testing for suspected Ebola virus infection in coordination with state and local public health authorities and CDC, as well as the benefits and limitations of existing diagnostic tools.
Date Last Updated (Year-Month-Day)
At the conclusion of the session, the participant will be able to accomplish the following:
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of health care providers.
Activity Specific Objectives
- Discuss procedures for assessing ill travelers returning from the outbreak area, including consultation with relevant public health authorities.
- Describe CDC’s role in providing technical support and testing approval for persons under investigation (PUI) for Ebola virus infection.
- Review the procedure for reporting and consulting on a suspected case of Ebola in the United States.
- Discuss considerations and limitations for domestic use of novel rapid diagnostic tests for Ebola.
- Discuss how to coordinate between clinicians, state health departments, and CDC as it pertains to domestic Ebola preparedness and diagnostics.
A few minutes before the webinar begins on Thursday, December 19, 2019, please click the link below to join the webinar:
Or iPhone one-tap:
US: +16468769923,,779319056# or +16699006833,,779319056#
Dial(for higher quality, dial a number based on your current location):
US: +1 646 876 9923 or +1 669 900 6833
Webinar ID: 804 256 797
International numbers available: https://zoom.us/u/anixAVglVexternal icon